TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05478200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: Group A (physical exercise, combined with pain education and healthy lifestyle habits), will receive an intervention programme consisting of 3 sessions per week for 12 weeks (total of 36 sessions). Each week there will be one face-to-face session, followed by 2 home sessions, (12 face-to-face and 24 home sessions). The sessions will include cardiovascular exercises, 2 days a week we will work on strength13 and 1 day a week we will work on mobility and exercises to improve movement control, both before the cardiovascular effort14 . Each session will include a light warm-up (at the beginning of the session) and a cool down (at the end).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Group B will receive a treatment based on passive analgesic techniques consisting of manual therapy, electrotherapy (interferential currents) and thermotherapy (microwaves). This treatment will be carried out in two weekly sessions (over eight weeks) of 40 minutes each, consisting of 15 minutes of manual therapy (of the lumbopelvic musculature), 10 minutes of electrotherapy (interferential current in the lumbar region) and thermotherapy (10 minutes local in the lumbar region).
Study: NCT04540432

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: 7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood test
Description: 7 ml of blood will be taken from each patient before treatment i.e. at the inclusion visit and at the end of treatment.
Study: NCT04890392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)
Description: S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
Study: NCT06224504

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychological nursing
Description: hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological nursing
Description: hen the patient has negative emotions, patiently listen to the patient's expression, and timely provide language comfort and guidance to the negative psychological emotions
Study: NCT05974904

Intervention type: OTHER
Intervention: high-sensitivity C-reactive protein to albumin ratio
Description: High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.

Intervention type: OTHER
Intervention: high-sensitivity C-reactive protein to albumin ratio
Description: High-sensitivity C-reactive protein to albumin ratio is an inflammatory indicator which can make a determination of disease severity.
Study: NCT06224504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR therapy
Description: Conducted in small groups once a week for 8 weeks, with each session lasting approximately 1-1.5 hours, encompassed mindfulness-based breathing exercises, dietary interventions, and body scans

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: Participants were assigned daily tasks for each session, requiring approximately 35-45 minutes per day
Study: NCT05874518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warm needling combined with electroacupuncture
Description: Treatment begins on the 5th day of the menstrual cycle, qd (once a day), usually for 6-8 consecutive days, and continuing to the day of ovulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The treatment with letrozole tablets was started on the fifth day of the menstrual cycle
Description: Letrozole tablets were given at 2.5mg (Jiangsu Hengrui Pharmaceutical Co., Ltd., H19991001, 2.5mg per tablet), po (oral), qd, for 5-7 consecutive days. When the diameter of follicles reaches 18mm, Chorionic gonadotrophin is given at 5000u (Lizhu Group Lizhu Pharmaceutical Factory, Chinese medicine H44020668, 5000u per branch), with intramuscular injection, qd, to promote follicle discharge. Patients were also instructed to have sexual intercourse on the same day and on day 2.
Study: NCT06566469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 µg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 0.2 mg/kg is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
Study: NCT05233410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT06566469

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline at the same volume is administered via nasal spray at 20:30 pm the day before surgery and at 07:30 am and 20:30 pm the day of surgery.
Study: NCT04325529

Intervention type: DEVICE
Intervention: Aversive stimuli
Description: Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).

Intervention type: DEVICE
Intervention: Aversive stimuli
Description: Electrotactile stimulation will be used as the aversive stimulus. The aversive stimulus is delivered in the form of a mild half-second stimulation to the ankle, calibrated to a subjective threshold that is uncomfortable but not painful. This stimulation is delivered by Digitimer DS8R Constant Current Stimulator (Digitimer North America, LLC. Ft. Lauderdale, FL). Its previous model DS71 has been safely implemented in studies with previously MGH-approved IRB's (Milad et al., 2013).
Study: NCT06566352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy with intramyometrial injection of diluted epinephrine
Description: intramyometrial injection of epinephrine 1mg diluted in 200mg of NaCl solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional laparoscopic myomectomy
Description: traditional laparoscopic myomectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic myomectomy with temporary bilateral uterine artery occlusion
Description: Experimental: laparoscopic myomectomy with temporary bilateral uterine artery occlusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of epinephrine 1mg diluted in 200mg of NaCl
Description: injection of epinephrine 1mg diluted in 200mg of NaCl
Study: NCT04813653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine in combination with carfilzomib and dexamethasone
Description: patients will be treated with cyclosporine with dose titration based on repeated determinations of whole blood concentrations to achieve a target trough concentration of 250 ng/mL, in combination with carfilzomib plus dexamethasone.
Study: NCT06346080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Discrete choice survey
Study: NCT06409325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MST
Description: MST was delivered with NS 7000 (Wuhan Yiruide Medical Equipment New Technology Co., Ltd.) using a round coil (125-mm diameter) positioned on the vertex.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECT
Description: The bitemporal ECT procedure utilized the Thymatron System IV device (Somatics, USA).
Study: NCT05046145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy for chewing + real tDCS
Description: participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy for chewing + real tDCS
Description: participants will be instructed to chew their food correctly during the tDCS session, but the participant does not know if the tdcs is real or sham.
Study: NCT05260528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine and Idarubicin
Description: Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-315
Description: Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3
Study: NCT06008470

Intervention type: OTHER
Intervention: observational tests
Description: Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity

Intervention type: OTHER
Intervention: observational tests
Description: Respiratory Muscle Strength Measurement In our study, respiratory muscle strength will be measured using a portable, electronic mouth pressure measuring device (MEC Pocket Spiro MPM100, Belgium). Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) measurement is one of the most commonly used non-invasive methods to evaluate respiratory muscles.~6 Minute Walk Test (6MWT): It has been used to assess physical activity and functional capacity in many pulmonary rehabilitation programs for patients with chronic pulmonary disease and limited respiratory capacity
Study: NCT05340153

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-Lumefantrine Drug Combination
Description: Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine drug combination
Description: Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
Study: NCT06109428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 125 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 1 g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1 g
Study: NCT05341427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electromagnetic device
Description: electromagnetic waves for burn wound
Study: NCT04827576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study: NCT06109428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luer lock applicator
Description: Applicator for instillation
Study: NCT04827576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle
Study: NCT06343077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poly-ICLC intramuscular (IM) injection
Description: 1.5 mg IM (week 1), followed by paired 1.5 mg IM weekly from weeks 3-through10, and at weeks 14, 18, 22, 26, 30, 34, 38, 42 and 46 with a 4-week rest period between IM injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poly-ICLC, Intertumoral (IT) injection
Description: 1 mg IT once (week 2)
Study: NCT05883605

Intervention type: DEVICE
Group type: OTHER
Intervention: Measuring blood pressure
Description: Measuring blood pressure using electronic device and using a mercury sphygmomanometer
Study: NCT04891939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education lessons (Smart-Kid's program)
Description: The intervention is designed for all students, including never-smokers and students at high risk for smoking. Therefore, some contents are intended to influence those high-risk youth within the larger student audience by targeting the stages of the smoking acquisition process including, preparation, initiation, experimentation, regular use, and addiction (Mayhew et al., 2000). The intervention is also focused on addressing risk factors for smoking initiation and continue use (Hansen et al., 2015; So \& Yeo, 2015). These risk factors are, therefore, grouped into four major groups namely; personal factors, behavioral factors, environmental factors and sociodemographic factors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School Health and Education Program (SHEP)
Description: The SHEP is the usual health and education program been done in all schools, and also has tobacco control component. This is will be used as the control for the intervention.
Study: NCT05980780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video game group
Description: Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a video game. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The game will be played at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education booklet group
Description: Pretest: Participants will be informed about FMF, treatment of FMF, side effects of treatment, factors that trigger attacks, symptoms that occur during the attack, symptom management/disease self-management, and coping with stress through a training booklet. At the beginning of the application, questions for the collection of demographic data and scales applied to the control group will be applied. The booklet will be read at home once a week for 1 month. For this, reminder messages will be sent once a week by obtaining the contact information of the mothers.~Post-test 1: The scales will be re-administered 1 month after the pre-test. Post-test 2: The scales will be administered again 3 months after the pre-test.
Study: NCT05345210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Fumarate+Amoxycillin 14days (VA14)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Fumarate+Amoxycillin 7days (VA7)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
Study: NCT06024876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS-101
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study: NCT04919967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual implementation protocol
Description: Participants assigned to the virtual implementation protocol plus e-learning/toolkit group will take the e-learning course and also receive additional assistance through Virtual Implementation support. The Virtual Implementation strategy will be provided through virtual assistance, training, and toolkits to help obstetric practices integrate perinatal mental health and obstetric care and is delivered over 2-3 months and includes two 1-hour virtual implementation e-meetings. Implementation will occur within the practice where a champion is identified who establishes a quality improvement team to implement the practice's change plan to achieve their goals of addressing perinatal mental health conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-learning toolkit
Description: A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-learning toolkit
Description: A toolkit given to obstetric care providers to enhance knowledge about and screening for perinatal mood and anxiety disorders. Participants assigned to the e-learning/toolkit alone group will take an e-learning course.This four-part online learning course aims to help obstetric care practitioners address perinatal mental health conditions such as depression, anxiety, PTSD and bipolar disorder.
Study: NCT06182267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L Arginine
Description: toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L Arginine
Description: toothpaste

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride
Description: toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride
Description: toothpaste
Study: NCT05951244

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)
Description: Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation-TessaNova (Teknofil-Turkiye)
Description: Sponge electrodes 5 x 7 cm in size will be used for tDCS application. The sponge electrodes will be wetted with saline and the cathode electrode will be placed on the seizure focus determined by EEG recording and seizure clinic, while the anode electrode will be placed on the contralateral shoulder-deltoid muscle.